TC
ACAD icon

TwinBeech Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

TwinBeech Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-253,795
Closed -$3.9M – 582
2024
Q3 		$3.9M Buy
+253,795
New +$4.23M 0.07% 296
2024
Q2 		– Sell
-142,496
Closed -$2.63M – 498
2024
Q1 		$2.63M Buy
+142,496
New +$3.53M 0.05% 303
2023
Q4 		– Sell
-316,555
Closed -$6.6M – 615
2023
Q3 		$6.6M Buy
316,555
+121,058
+62% +$3.29M 0.13% 217
2023
Q2 		$4.68M Buy
195,497
+79,798
+69% +$1.77M 0.09% 246
2023
Q1 		$2.18M Buy
+115,699
New +$2.2M 0.04% 359
2022
Q3 		– Sell
-79,579
Closed -$1.12M – 591
2022
Q2 		$1.12M Buy
+79,579
New +$1.49M 0.05% 307
2022
Q1 		– Sell
-21,366
Closed -$499K – 471
2021
Q4 		$499K Buy
+21,366
New +$430K 0.03% 423
2021
Q2 		– Sell
-29,975
Closed -$773K – 424
2021
Q1 		$773K Buy
29,975
+25,941
+643% +$1.14M 0.11% 229
2020
Q4 		$216K Sell
4,034
-14,253
-78% -$708K 0.04% 403
2020
Q3 		$754K Buy
+18,287
New +$790K 0.16% 192

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

TwinBeech Capital's ACAD Position: Q4 2024 in Review

TwinBeech Capital sold out of Acadia Pharmaceuticals (ACAD) in Q4 2024, closing a stake of 253,795 shares — an estimated $3.9M sold.

TwinBeech Capital first reported a position in ACAD in Q3 2020 and held it in 10 quarters. The position peaked at $6.6M in Q3 2023. 296 funds tracked by Wall St. Rank hold ACAD as of Q4 2024.

  • TwinBeech Capital reported no remaining Acadia Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • TwinBeech Capital sold 253,795 Acadia Pharmaceuticals shares in Q4 2024, an estimated $3.9M.
  • TwinBeech Capital first reported a position in Acadia Pharmaceuticals in Q3 2020 and held it in 10 quarters.
  • TwinBeech Capital's Acadia Pharmaceuticals position peaked at $6.6M in Q3 2023.
  • 296 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2024.

Based on TwinBeech Capital's 13F filing for Q4 2024, filed 14 Feb 2025.